Search results
Results from the WOW.Com Content Network
Serious side effects may include low blood pressure or heart attack. [10] Whether use is safe during pregnancy or breastfeeding is unclear. [2] [10] When used by people with liver problems, and in elderly individuals, doses should be reduced. [10] Amlodipine works partly by vasodilation (relaxing the arteries and increasing their diameter). [10]
The Federal Trade Commission (FTC), along with the New York State Attorney General's office, is angling to give a Wisconsin-based supplement company a legal battle it won't soon forget.Their case ...
Amlodipine/benazepril, sold under the brand name Lotrel among others, is a fixed-dose combination medication used to treat high blood pressure. [1] It is a combination of amlodipine , as the besilate, a calcium channel blocker , and benazepril , an angiotensin converting enzyme inhibitor . [ 1 ]
Levamlodipine , also known as levoamlodipine or S-amlodipine is a pharmacologically active enantiomer of amlodipine. [1] Amlodipine belongs to the dihydropyridine group of calcium channel blocker used as an antihypertensive and antianginal agent. [2] It was approved by the U.S. FDA in December 2019 and is currently marketed under the brand name ...
Contraindications include the coadministration of terfenadine, astemizole, cisapride, pimozide, or carbamazepine.Nefazodone is contraindicated in patients who were withdrawn from nefazodone because of evident liver injury as well as those that have shown hypersensitivity to the drug, its inactive ingredients, or other phenylpiperazine antidepressants.
Amlodipine/celecoxib, sold under the brand name Consensi, is a fixed-dose combination medication used to treat both hypertension and osteoarthritis at the same time in adults. [ 1 ] [ 2 ] It contains amlodipine , as the besilate, and celecoxib . [ 1 ]
In May 2001, Bridgepoint closed its first fund following its independence from NatWest. The fund closed at €2 billion, and made its first investments in WT Foods, Virgin Active and Hydrex. [5] The firm closed its Europe II fund in 2001 [6] and its Europe III fund in 2005. [7] [8] Bridgepoint closed its Europe IV fund in 2008 for €4.8 ...
Critics have long argued that while studying the effects of Red Dye No. 3 in humans poses ethical and scientific challenges, its ban in cosmetics should have logically extended to the food supply.